Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer
Small Cell Lung Carcinoma
Explore 277 assets in Small Cell Lung Carcinoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04938817CT.gov Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer (this asset) | Merck Sharp & Dohme LLC | P1/2 | CC · 45 |
| Benmelstobart | Yayi He | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Irinotecan | Sichuan University | P4 | BB |
| Nogitecan | AbbVie | P4 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | B · 61 |
| Hepatocellular Carcinoma | — | P2 | CCC · 52 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-cytotoxic-t-lymphocyte-associated-antigen-4-human-mus-musculus-monoclonal-m3-gamma1-chain-disulfide-with-human-mus-musculus-monoclonal-m3-kappa-chain-dimer-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →